| 1 |
34729910 | Investigating interactions between chloroquine/hydroxychloroquine and their single enantiomers and angiotensin-converting enzyme 2 by a cell membrane chromatography method. | 2022 Jan |
7 |
| 2 |
34741481 | Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine. | 2022 Feb |
1 |
| 3 |
34826419 | Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells. | 2022 Jan |
3 |
| 4 |
32677545 | Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study. | 2021 Sep |
3 |
| 5 |
32696720 | Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19. | 2021 Oct |
1 |
| 6 |
32752951 | Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2. | 2021 Nov |
1 |
| 7 |
32770567 | Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study. | 2021 Feb |
1 |
| 8 |
33706683 | Potential inhibitors of angiotensin converting enzyme 2 receptor of COVID-19 by Corchorus olitorius Linn using docking, molecular dynamics, conceptual DFT investigation and pharmacophore mapping. | 2021 Mar 11 |
1 |
| 9 |
34017843 | ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes. | 2021 |
1 |
| 10 |
34130375 | Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective. | 2021 Jun |
1 |
| 11 |
34337036 | Characterization of the Modulatory Effect of Hydroxychloroquine on ACE2 Activity: New Insights in relation to COVID-19. | 2021 |
5 |
| 12 |
34568544 | Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach. | 2021 |
2 |
| 13 |
32402766 | Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. | 2020 Sep |
2 |
| 14 |
32522067 | Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. | 2020 Dec |
2 |
| 15 |
32664879 | New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. | 2020 Jul 15 |
1 |
| 16 |
32738306 | In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. | 2020 Sep |
2 |
| 17 |
32784543 | Are the Clinical Presentations (Phenotypes) of Gitelman's and Bartter's Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their "pH" Enotype? | 2020 Aug 7 |
1 |
| 18 |
32817933 | Hydroxychloroquine: mechanism of action inhibiting SARS-CoV2 entry. | 2020 Oct 30 |
2 |
| 19 |
32878881 | De novo design, retrosynthetic analysis and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2. | 2020 Oct 15 |
1 |
| 20 |
32920291 | Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus. | 2020 Dec |
7 |
| 21 |
33117441 | Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome - Clearing Safety Issues and Good Clinical Practice. | 2020 Oct |
1 |